

Garth T Whiteside

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1498683/publications.pdf>

Version: 2024-02-01

52
papers

3,196
citations

186209

28
h-index

182361

51
g-index

52
all docs

52
docs citations

52
times ranked

4120
citing authors

#	ARTICLE	IF	CITATIONS
1	Loss of Retrograde Endocannabinoid Signaling and Reduced Adult Neurogenesis in Diacylglycerol Lipase Knock-out Mice. <i>Journal of Neuroscience</i> , 2010, 30, 2017-2024.	1.7	404
2	Pharmacological and pharmacokinetic characterization of the cannabinoid receptor 2 agonist, GW405833, utilizing rodent models of acute and chronic pain, anxiety, ataxia and catalepsy. <i>Neuropharmacology</i> , 2005, 48, 658-672.	2.0	256
3	Monoacylglycerol Lipase Activity Is a Critical Modulator of the Tone and Integrity of the Endocannabinoid System. <i>Molecular Pharmacology</i> , 2010, 78, 996-1003.	1.0	205
4	Targeting CB2 receptors and the endocannabinoid system for the treatment of pain. <i>Brain Research Reviews</i> , 2009, 60, 255-266.	9.1	180
5	Depression-like phenotype following chronic CB1 receptor antagonism. <i>Neurobiology of Disease</i> , 2010, 39, 148-155.	2.1	142
6	Pharmacological characterisation of a rat model of incisional pain. <i>British Journal of Pharmacology</i> , 2004, 141, 85-91.	2.7	141
7	Cell death in the superficial dorsal horn in a model of neuropathic pain. <i>Journal of Neuroscience Research</i> , 2001, 64, 168-173.	1.3	126
8	The Role of the Cannabinoid CB2 Receptor in Pain Transmission and Therapeutic Potential of Small Molecule CB2 Receptor Agonists. <i>Current Medicinal Chemistry</i> , 2007, 14, 917-936.	1.2	125
9	Dynamic Changes in the MicroRNA Expression Profile Reveal Multiple Regulatory Mechanisms in the Spinal Nerve Ligation Model of Neuropathic Pain. <i>PLoS ONE</i> , 2011, 6, e17670.	1.1	123
10	Predictive validity of animal pain models? A comparison of the pharmacokineticâ€“pharmacodynamic relationship for pain drugs in rats and humans. <i>Neuropharmacology</i> , 2008, 54, 767-775.	2.0	120
11	Inhibition of osteoclasts prevents cartilage loss and pain in a rat model of degenerative joint disease. <i>Osteoarthritis and Cartilage</i> , 2010, 18, 1319-1328.	0.6	110
12	A role for cannabinoid receptors, but not endogenous opioids, in the antinociceptive activity of the CB2-selective agonist, GW405833. <i>European Journal of Pharmacology</i> , 2005, 528, 65-72.	1.7	87
13	Modifications to the hand-held Gene Gun: improvements for in vitro Biolistic transfection of organotypic neuronal tissue. <i>Journal of Neuroscience Methods</i> , 2001, 112, 57-64.	1.3	82
14	Species-specific in vitro pharmacological effects of the cannabinoid receptor 2 (CB2) selective ligand AM1241 and its resolved enantiomers. <i>British Journal of Pharmacology</i> , 2007, 151, 1061-1070.	2.7	78
15	A-317491, a selective P2X3/P2X2/3 receptor antagonist, reverses inflammatory mechanical hyperalgesia through action at peripheral receptors in rats. <i>European Journal of Pharmacology</i> , 2004, 504, 45-53.	1.7	74
16	The persistence of a long-term negative affective state following the induction of either acute or chronic pain. <i>Pain</i> , 2008, 140, 436-445.	2.0	73
17	Negative allosteric modulation of metabotropic glutamate receptor 5 results in broad spectrum activity relevant to treatment resistant depression. <i>Neuropharmacology</i> , 2013, 66, 202-214.	2.0	71
18	Ensuring transparency and minimization of methodologic bias in preclinical pain research. <i>Pain</i> , 2016, 157, 901-909.	2.0	70

#	ARTICLE	IF	CITATIONS
19	Abnormal gait, due to inflammation but not nerve injury, reflects enhanced nociception in preclinical pain models. <i>Brain Research</i> , 2009, 1295, 89-98.	1.1	57
20	Estrogen Receptor Neurobiology and its Potential for Translation into Broad Spectrum Therapeutics for CNS Disorders. <i>Current Molecular Pharmacology</i> , 2009, 2, 215-236.	0.7	52
21	An industry perspective on the role and utility of animal models of pain in drug discovery. <i>Neuroscience Letters</i> , 2013, 557, 65-72.	1.0	49
22	An improved method for detection of apoptosis in tissue sections and cell culture, using the TUNEL technique combined with Hoechst stain. <i>Brain Research Protocols</i> , 1998, 2, 160-164.	1.7	48
23	Differential time course of neuronal and glial apoptosis in neonatal rat dorsal root ganglia after sciatic nerve axotomy. <i>European Journal of Neuroscience</i> , 1998, 10, 3400-3408.	1.2	40
24	Pain is a salient stressor that is mediated by corticotropin-releasing factor-1 receptors. <i>Neuropharmacology</i> , 2010, 59, 160-166.	2.0	39
25	The Role of Central and Peripheral μ Opioid Receptors in Inflammatory Pain and Edema: A Study Using Morphine and DiPOA ([8-(3,3-Diphenyl-propyl)-4-oxo-1-phenyl-1,3,8-triaza-spiro[4.5]dec-3-yl]-acetic Acid). <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2005, 314, 1234-1240.	1.3	36
26	Pharmacology of 2-[4-(4-Chloro-2-fluorophenoxy)phenyl]-pyrimidine-4-carboxamide: A Potent, Broad-Spectrum State-Dependent Sodium Channel Blocker for Treating Pain States. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2006, 318, 1083-1093.	1.3	35
27	Pharmacological Characterization of the Muscarinic Agonist (3R,4R)-3-(3-Hexylsulfanyl-pyrazin-2-yloxy)-1-aza-bicyclo[2.2.1]heptane (WAY-132983) in in Vitro and in Vivo Models of Chronic Pain. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2007, 322, 1294-1304.	1.3	35
28	A randomized, double-blind, positive-controlled, 3-way cross-over human experimental pain study of a TRPV1 antagonist (V116517) in healthy volunteers and comparison with preclinical profile. <i>Pain</i> , 2016, 157, 2057-2067.	2.0	29
29	Genetic and Functional Analysis of Human P2X5 Reveals a Distinct Pattern of Exon 10 Polymorphism with Predominant Expression of the Nonfunctional Receptor Isoform. <i>Molecular Pharmacology</i> , 2010, 77, 953-960.	1.0	28
30	CNS penetration of small molecules following local inflammation, widespread systemic inflammation or direct injury to the nervous system. <i>Life Sciences</i> , 2009, 85, 450-456.	2.0	26
31	Neuropathy-induced osteopenia in rats is not due to a reduction in weight born on the affected limb. <i>Bone</i> , 2006, 38, 387-393.	1.4	23
32	1- or 3-(3-Amino-2-hydroxy-1-phenyl propyl)-1,3-dihydro-2H-benzimidazol-2-ones: Potent, Selective, and Orally Efficacious Norepinephrine Reuptake Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2009, 52, 5703-5711.	2.9	23
33	1-(Indolin-1-yl)-1-phenyl-3-propan-2-olamines as Potent and Selective Norepinephrine Reuptake Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2010, 53, 2051-2062.	2.9	22
34	DiPOA ([8-(3,3-Diphenyl-propyl)-4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]dec-3-yl]-acetic Acid), a Novel, Systemically Available, and Peripherally Restricted μ Opioid Agonist with Antihyperalgesic Activity: II. In Vivo Pharmacological Characterization in the Rat. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2004, 310, 793-799.	1.3	20
35	Purinergic receptor-mediated morphological changes in microglia are transient and independent from inflammatory cytokine release. <i>European Journal of Pharmacology</i> , 2010, 643, 202-210.	1.7	18
36	Discovery of Novel Selective Norepinephrine Reuptake Inhibitors: 4-[3-Aryl-2,2-dioxido-2,1,3-benzothiadiazol-1(3H)-yl]-1-(methylamino)butan-2-ols (WYE-103231). <i>Journal of Medicinal Chemistry</i> , 2010, 53, 4511-4521.	2.9	15

#	ARTICLE	IF	CITATIONS
37	Anatomical localization and expression pattern for the NMDA-2D receptor subunit in a rat model of neuropathic pain. <i>Neuroscience</i> , 2008, 155, 492-502.	1.1	13
38	Tri-partite complex for axonal transport drug delivery achieves pharmacological effect. <i>BMC Neuroscience</i> , 2010, 11, 8.	0.8	13
39	Inflammatory Cytokine and Chemokine Expression Is Differentially Modulated Acutely in the Dorsal Root Ganglion in Response to Different Nerve Root Compressions. <i>Spine</i> , 2011, 36, 197-202.	1.0	13
40	Age-dependent effects of the cannabinoid CB1 antagonist SR141716A on food intake, body weight change, and pruritus in rats. <i>Psychopharmacology</i> , 2009, 206, 155-165.	1.5	12
41	Effect of colchicine on neuropeptide Y expression in rat dorsal root ganglia and spinal cord. <i>Neuroscience Letters</i> , 1999, 259, 45-48.	1.0	10
42	WAY-18068: a novel, potent and selective noradrenaline reuptake inhibitor with activity in rodent models of pain and depression. <i>British Journal of Pharmacology</i> , 2010, 160, 1105-1118.	2.7	10
43	Advances in the development of novel analgesics. <i>Expert Opinion on Therapeutic Patents</i> , 2008, 18, 1027-1067.	2.4	9
44	Measuring and realizing the translational significance of preclinical in vivo studies of painful osteoarthritis. <i>Osteoarthritis and Cartilage</i> , 2017, 25, 376-384.	0.6	9
45	Current and potential pharmacological treatment options for insomnia in patients with alcohol use disorder in recovery. <i>Neuropsychopharmacology Reports</i> , 2020, 40, 211-223.	1.1	9
46	Structure-activity relationships of norepinephrine reuptake inhibitors with benzothiadiazine dioxide or dihydrosulfostyryl cores. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2010, 20, 1555-1558.	1.0	8
47	Discovery of Novel Selective Norepinephrine Inhibitors: 1-(2-Morpholin-2-ylethyl)-3-aryl-1,3-dihydro-2,1,3-benzothiadiazole 2,2-Dioxides (WYE-114152). <i>Journal of Medicinal Chemistry</i> , 2011, 54, 6824-6831.	2.9	8
48	Preclinical Pharmacological Approaches in Drug Discovery for Chronic Pain. <i>Advances in Pharmacology</i> , 2016, 75, 303-323.	1.2	8
49	A Review of the NOP (ORL-1)-Nociceptin/Orphanin FQ System Covering Receptor Structure, Distribution, Role in Analgesia and Reward and Interactions with Other Receptors. <i>ACS Symposium Series</i> , 2013, , 327-368.	0.5	6
50	Robustness of arterial blood gas analysis for assessment of respiratory safety pharmacology in rats. <i>Journal of Pharmacological and Toxicological Methods</i> , 2016, 78, 32-41.	0.3	5
51	Pharmacological evaluation of NSAID-induced gastropathy as a "Translatable" model of referred visceral sensitivity. <i>World Journal of Gastroenterology</i> , 2017, 23, 6065-6076.	1.4	1
52	Successful use of axonal transport for drug delivery by synthetic molecular vehicles. <i>Nature Precedings</i> , 2008, , .	0.1	0